LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Elenco Azioni・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

94.02 -1.67

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

92.66

Massimo

96.23

Metriche Chiave
By Trading Economics
Entrata	5.4M -48M
Vendite	6M 57M
Margine di Profitto	-82.974
Dipendenti	414
EBITDA	5.1M -43M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+41.41% upside

Dividendi
By Dow Jones
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-565M 5.9B
Apertura precedente	95.69
Chiusura precedente	94.02

Notizie sul Sentiment di mercato

By Acuity

48%

52%

160 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

60 / 65.58 Supporto e resistenza

Rhythm Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 mag 2026, 23:58 UTC

Utili

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mag 2026, 22:57 UTC

Utili

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mag 2026, 23:52 UTC

Utili

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mag 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mag 2026, 23:28 UTC

Discorsi di Mercato

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mag 2026, 23:11 UTC

Utili

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mag 2026, 23:06 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mag 2026, 23:05 UTC

Utili

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mag 2026, 23:04 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mag 2026, 23:03 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mag 2026, 23:03 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mag 2026, 23:02 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mag 2026, 23:00 UTC

Discorsi di Mercato

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mag 2026, 22:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 mag 2026, 22:45 UTC

Discorsi di Mercato

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mag 2026, 22:42 UTC

Utili

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mag 2026, 22:33 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mag 2026, 22:32 UTC

Utili

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mag 2026, 22:31 UTC

Utili

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mag 2026, 22:31 UTC

Utili

Macquarie: 68% of FY Income From International >MQG.AU

7 mag 2026, 22:30 UTC

Utili

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mag 2026, 22:30 UTC

Utili

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mag 2026, 22:29 UTC

Utili

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mag 2026, 22:28 UTC

Utili

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mag 2026, 22:28 UTC

Utili

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mag 2026, 22:27 UTC

Utili

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mag 2026, 22:27 UTC

Utili

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mag 2026, 22:26 UTC

Utili

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mag 2026, 22:25 UTC

Utili

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Confronto tra pari

Modifica del prezzo

Rhythm Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

41.41% in crescita

Previsioni per 12 mesi

Media 136.62 USD 41.41%

Alto 158 USD

Basso 105 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 14 che hanno fornito valutazioni azionarie a Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

60 / 65.58Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

160 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.